MYD88 and ovarian cancer: As all three biomarkers have been shown, individually, to have a significant impact on patient prognosis and the modulation of paclitaxel chemoresponsiveness and also given the fact that many cytokines secreted during senescence are also known downstream targets of TLR4-MyD88 signalling we hypothesised that there may be crosstalk between these three important biomarkers in ovarian cancer.